Company / EPS (Diluted)
Amylyx Pharmaceuticals, Inc. EPS (Diluted) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.53
FY2025
5-year range
-$13.35 / $0.70
FY2021-FY2025
Trend
+65.5%
vs FY2024
Sector context
#110 of 204
Health Care
What the data says
At $-1.53, Amylyx Pharmaceuticals, Inc.'s eps (diluted) ranks #110 of 204 in the Health Care sector. Declined from $0.70 to $-1.53 over the past 2 years.
Based on SEC 10-K filings.
-1.53 in FY2025.
Declined from $0.70 to $-1.53 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#110 of 204 in Health CareTop 54% of 204This company -$1.53 Sector average -$0.89
▼
-72.6% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 65.5% year-over-year.
- Ranks #110 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.53 | +65.5% |
| FY2024 | -$4.43 | -732.9% |
| FY2023 | $0.70 | +105.2% |
| FY2022 | -$13.35 | +0.0% |
| FY2021 | -$13.35 | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026